Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT01251250 | Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 0 | Jan 13, 2014 |
| NCT00028613 | Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma | completed | Phase 1 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 9, 2014 | clinicaltrials |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma(AAV) | terminated | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jan 8, 2014 | clinicaltrials |
| NCT00769288 | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 7, 2014 | clinicaltrials |
| NCT01068301 | A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation | completed | Phase 1 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Jan 1, 2014 | clinicaltrials |
| NCT01479023 | Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 12 | Washington University School of MedicineOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT00004036 | Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer | unknown | Phase 1 | 30 | The Cleveland ClinicOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00040950 | Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2013 | clinicaltrials |
| NCT00006100 | Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma | unknown | Phase 1 | — | Milton S. Hershey Medical CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00007839 | Beta Alethine in Treating Patients With Low-Grade Lymphoma | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00041379 | Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | — | LifeTime PharmaceuticalsINDUSTRY | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00033423 | Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 | 18 | University of Alabama at BirminghamOTHER | 1 | Dec 13, 2013 | clinicaltrials |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation(WT-1) | terminated | Phase 1 | 8 | Michael Morse, MDOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00911066 | MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia | completed | Phase 1 | 72 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2013 | clinicaltrials |
| NCT00003942 | Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 15 | SystemixINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00957320 | Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL) | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT01129180 | Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma | completed | Phase 1 | 8 | Pierluigi PorcuOTHER | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00985959 | A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT) | completed | Phase 1 | 101 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT01697020 | Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions | completed | Phase 1 | 70 | Nova Laboratories LimitedINDUSTRY | 1 | Dec 2, 2013 | clinicaltrials |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT00722488 | Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma | completed | Phase 1 | 56 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT01823718 | Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes | unknown | Phase 1 | 18 | Nantes University HospitalOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT01205737 | A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects | completed | Phase 1 | 186 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 10 | Oct 22, 2013 | clinicaltrials |
| NCT00003356 | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | completed | Phase 1 / Phase 2 | 58 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00016016 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00068315 | Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00079378 | Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00098423 | Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00293345 | 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00301938 | 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00398515 | Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | completed | Phase 1 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00470197 | Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00612612 | Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | terminated | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01185262 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia(LLC-LENAR-08) | completed | Phase 1 | 25 | MD Anderson International Spain SAOTHER | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00004858 | Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | Parker Hughes Cancer CenterOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00009776 | Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | University of California, DavisOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00023816 | Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma | unknown | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 0 | Sep 20, 2013 | clinicaltrials |
| NCT00031902 | Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 | — | Lymphoma Trials OfficeOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00032149 | Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Lymphoma Trials OfficeOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00363090 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 84 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jan 20, 2014source: clinicaltrials